Perspective Therapeutics (CATX) to Release Quarterly Earnings on Wednesday

Perspective Therapeutics (NYSE:CATX) will likely be releasing its earnings data after the market closes on Wednesday, March 26th. Analysts expect Perspective Therapeutics to post earnings of ($0.26) per share for the quarter.

Perspective Therapeutics Price Performance

NYSE CATX opened at $2.52 on Tuesday. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05. The business has a fifty day moving average of $3.01 and a 200-day moving average of $6.66.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $24.00 to $5.00 in a report on Monday, November 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $14.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.